Literature DB >> 19937159

HTR2A is associated with SSRI response in major depressive disorder in a Japanese cohort.

Taro Kishi1, Reiji Yoshimura, Tsuyoshi Kitajima, Tomo Okochi, Takenori Okumura, Tomoko Tsunoka, Yoshio Yamanouchi, Yoko Kinoshita, Kunihiro Kawashima, Hiroshi Naitoh, Jun Nakamura, Norio Ozaki, Nakao Iwata.   

Abstract

Several recent investigations reported that the serotonin 2A receptor gene (HTR2A) was associated with selective serotonin reuptake inhibitors (SSRIs) in major depressive disorder. There have also been two reported association analyses of HTR2A with SSRI response in Japanese MDD patients, but the results were rather inconsistent and both studies had the problem of small sample sizes. Therefore, we conducted a replication association study using a sample larger than those in the two original Japanese studies (265 MDD patients), and found that four SNPs, two functional SNPs (-A1438G: rs6311 and T102C: rs6313) and two SNPs (rs7997012 and rs1928040) in HTR2A, were associated with the therapeutic response to SSRIs. HTR2A was associated with the therapeutic response SSRIs in Japanese MDD patients in a haplotype-wise analysis (P(all markers) = 0.0136), and a significant association between rs1928040 in HTR2A and SSRI response was detected in MDD (P(allele-wise analysis) = 0.0252). However, this significance disappeared after Bonferroni correction (P(allele-wise analysis) = 0.101). In conclusion, we suggest that HTR2A may play an important role in the pathophysiology of the therapeutic response to SSRIs in Japanese MDD patients. However, it will be important to replicate and confirm these findings in other independent studies using large samples.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19937159     DOI: 10.1007/s12017-009-8105-y

Source DB:  PubMed          Journal:  Neuromolecular Med        ISSN: 1535-1084            Impact factor:   3.843


  28 in total

1.  Pedigree disequilibrium tests for multilocus haplotypes.

Authors:  Frank Dudbridge
Journal:  Genet Epidemiol       Date:  2003-09       Impact factor: 2.135

2.  Genetic Power Calculator: design of linkage and association genetic mapping studies of complex traits.

Authors:  S Purcell; S S Cherny; P C Sham
Journal:  Bioinformatics       Date:  2003-01       Impact factor: 6.937

3.  Selective serotonin reuptake inhibitors: THREAD trial may show way forward.

Authors:  Robert Peveler; Tony Kendrick
Journal:  BMJ       Date:  2005-02-19

4.  Effects of the serotonin type 2A, 3A and 3B receptor and the serotonin transporter genes on paroxetine and fluvoxamine efficacy and adverse drug reactions in depressed Japanese patients.

Authors:  Masaki Kato; Tsuyoshi Fukuda; Masataka Wakeno; Kazuhiro Fukuda; Gaku Okugawa; Yuka Ikenaga; Megumi Yamashita; Yoshiteru Takekita; Kenji Nobuhara; Junichi Azuma; Toshihiko Kinoshita
Journal:  Neuropsychobiology       Date:  2006-07-26       Impact factor: 2.328

5.  Association analysis of nuclear receptor Rev-erb alpha gene (NR1D1) with mood disorders in the Japanese population.

Authors:  Taro Kishi; Tsuyoshi Kitajima; Masashi Ikeda; Yoshio Yamanouchi; Yoko Kinoshita; Kunihiro Kawashima; Tomo Okochi; Norio Ozaki; Nakao Iwata
Journal:  Neurosci Res       Date:  2008-08-30       Impact factor: 3.304

Review 6.  Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder.

Authors:  M Kato; A Serretti
Journal:  Mol Psychiatry       Date:  2008-11-04       Impact factor: 15.992

Review 7.  From molecular biology to pharmacogenetics: a review of the literature on antidepressant treatment and suggestions of possible candidate genes.

Authors:  Alessandro Serretti; Paola Artioli
Journal:  Psychopharmacology (Berl)       Date:  2004-03-02       Impact factor: 4.530

Review 8.  HTR2A gene variants and psychiatric disorders: a review of current literature and selection of SNPs for future studies.

Authors:  Alessandro Serretti; Antonio Drago; Diana De Ronchi
Journal:  Curr Med Chem       Date:  2007       Impact factor: 4.530

9.  A structured interview guide for the Hamilton Depression Rating Scale.

Authors:  J B Williams
Journal:  Arch Gen Psychiatry       Date:  1988-08

10.  A family based association study of T102C polymorphism in 5HT2A and schizophrenia plus identification of new polymorphisms in the promoter.

Authors:  G Spurlock; A Heils; P Holmans; J Williams; U M D'Souza; A Cardno; K C Murphy; L Jones; P R Buckland; P McGuffin; K P Lesch; M J Owen
Journal:  Mol Psychiatry       Date:  1998-01       Impact factor: 15.992

View more
  20 in total

Review 1.  Pharmacogenetics of antidepressants, mood stabilizers, and antipsychotics in diverse human populations.

Authors:  Eleanor Murphy; Francis J McMahon
Journal:  Discov Med       Date:  2013-09       Impact factor: 2.970

Review 2.  Pharmacogenetics of major depressive disorder: top genes and pathways toward clinical applications.

Authors:  Chiara Fabbri; Alessandro Serretti
Journal:  Curr Psychiatry Rep       Date:  2015-07       Impact factor: 5.285

Review 3.  Pharmacogenetics and Imaging-Pharmacogenetics of Antidepressant Response: Towards Translational Strategies.

Authors:  Tristram A Lett; Henrik Walter; Eva J Brandl
Journal:  CNS Drugs       Date:  2016-12       Impact factor: 5.749

4.  The phenotype, psychotype and genotype of bruxism.

Authors:  Norma Cruz-Fierro; Margarita Martínez-Fierro; Ricardo M Cerda-Flores; Mayra A Gómez-Govea; Iván Delgado-Enciso; Laura E Martínez-De-Villarreal; Mónica T González-Ramírez; Irám Pablo Rodríguez-Sánchez
Journal:  Biomed Rep       Date:  2018-01-15

5.  5-HT₂A receptor inactivation potentiates the acute antidepressant-like activity of escitalopram: involvement of the noradrenergic system.

Authors:  G Quesseveur; C Repérant; D J David; A M Gardier; C Sanchez; B P Guiard
Journal:  Exp Brain Res       Date:  2013-02-15       Impact factor: 1.972

6.  Race, genetic ancestry and response to antidepressant treatment for major depression.

Authors:  Eleanor Murphy; Liping Hou; Brion S Maher; Girma Woldehawariat; Layla Kassem; Nirmala Akula; Gonzalo Laje; Francis J McMahon
Journal:  Neuropsychopharmacology       Date:  2013-07-05       Impact factor: 7.853

7.  Lack of association between MAGEL2 and schizophrenia and mood disorders in the Japanese population.

Authors:  Yasuhisa Fukuo; Taro Kishi; Tomo Okochi; Tsuyoshi Kitajima; Tomoko Tsunoka; Takenori Okumukura; Yoko Kinoshita; Kunihiro Kawashima; Yoshio Yamanouchi; Wakako Umene-Nakano; Hiroshi Naitoh; Toshiya Inada; Reiji Yoshimura; Jun Nakamura; Norio Ozaki; Nakao Iwata
Journal:  Neuromolecular Med       Date:  2010-05-14       Impact factor: 3.843

8.  Role of the 5-HT₂A receptor in the locomotor hyperactivity produced by phenylalkylamine hallucinogens in mice.

Authors:  Adam L Halberstadt; Susan B Powell; Mark A Geyer
Journal:  Neuropharmacology       Date:  2013-01-29       Impact factor: 5.250

Review 9.  From pharmacogenetics to pharmacogenomics: the way toward the personalization of antidepressant treatment.

Authors:  Chiara Fabbri; Stefano Porcelli; Alessandro Serretti
Journal:  Can J Psychiatry       Date:  2014-02       Impact factor: 4.356

10.  Associations between the 1438A/G, 102T/C, and rs7997012G/A polymorphisms of HTR2A and the safety and efficacy of antidepressants in depression: a meta-analysis.

Authors:  Yuan-Sheng Wan; Xue-Jia Zhai; You-Sheng Ai; Li-Bo Zhao; Hong-Ai Tan
Journal:  Pharmacogenomics J       Date:  2020-10-23       Impact factor: 3.550

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.